Raines and colleagues have developed an engineered variant of the RNase1 protein that targets RNAs in cancer cells by diminishing the protein's association with a natural RNase inhibitor in the cytosol, which is undergoing clinical trials as an anti-cancer agent in non-small cell lung and ovarian cancers 69. The gene discussed is RNASE1; the disease is ovarian cancer.